Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (441-450 of 616) with videos related to

Pageof 62
Sort By:
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 19, 2005
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injuryChao-Hung Wang, Shu-Hong Li, Richard D Weisel, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertensionBiswajit Chowdhury, Albert Z Luu, Vincent Z Luu, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
Journal of the American College of Cardiology|June 24, 2024
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF ProgramMorten Schou, Mark C Petrie, Barry A Borlaug, et al.
Circulation|April 14, 2004
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular diseaseSubodh Verma, Michael A Kuliszewski, Shu-Hong Li, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
European Journal of Heart Failure|October 24, 2022
Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trialKershaw V Patel, Muhammad Shahzeb Khan, Matthew W Segar, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 30, 2023
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-PreservedAndrew J S Coats, Javed Butler, Hiroyuki Tsutsui, et al.
European Heart Journal|June 29, 2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialCarolyn S P Lam, João Pedro Ferreira, Egon Pfarr, et al.
Circulation|April 4, 2022
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70Brian A Bergmark, Nicholas A Marston, Candace R Bramson, et al.
Pageof 62

Showing results (441-450 of 616) with videos related to

Sort By:
Pageof 62
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|March 19, 2005
Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injuryChao-Hung Wang, Shu-Hong Li, Richard D Weisel, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertensionBiswajit Chowdhury, Albert Z Luu, Vincent Z Luu, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
Journal of the American College of Cardiology|June 24, 2024
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF ProgramMorten Schou, Mark C Petrie, Barry A Borlaug, et al.
Circulation|April 14, 2004
C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular diseaseSubodh Verma, Michael A Kuliszewski, Shu-Hong Li, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
European Journal of Heart Failure|October 24, 2022
Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trialKershaw V Patel, Muhammad Shahzeb Khan, Matthew W Segar, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 30, 2023
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-PreservedAndrew J S Coats, Javed Butler, Hiroyuki Tsutsui, et al.
European Heart Journal|June 29, 2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialCarolyn S P Lam, João Pedro Ferreira, Egon Pfarr, et al.
Circulation|April 4, 2022
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70Brian A Bergmark, Nicholas A Marston, Candace R Bramson, et al.
Pageof 62